Sirius Medical proudly announces implant with Sirius Pintuition in Royal Marsden, UK
Sirius Medical announces FDA 510(k) Clearance of Sirius Pintuition for Breast Cancer Surgery
Sirius Medical and Edimex are pleased to announce that Edimex will be the exclusive French distributor of Sirius Pintuition, a novel localization system for non-palpable breast tumors.
Sirius Medical announces two new members to its clinical advisory board: Alexander van Akkooi and Carolina Sobrido Sampedro.
Safety and performance of Sirius Pintuition – a novel wire-free and nonradioactive localization system for breast cancer surgery.
Sirius Medical is proud to presents first clinical results about Sirius Pintuition during virtual ESSO 2020.
A safety and performance study was performed in Jeroen Bosch hospital and the first global commercial implants took place in Elisabeth-TweeSteden hospital, The Netherlands
De eerste klinische resultaten van de Sirius Pintuition, een nieuwe draadloze lokalisatie techniek voor borstsparende operaties
Sirius Medical organiseert een webinar van de eerste klinische onderzoeksresultaten van de Sirius Pintuition.
Sirius Medical is present at EBCC-12 conference with a virtual booth. Please visit us in this unique interactive environment to learn more about the Sirius Pintuition System.
Sirius Medical is excited to announce that it has successfully raised €4.4M to accelerate the commercial launch of the Sirius Pintuition System for cancer localization and to develop a pipeline of complementary products and indications.
Sirius Medical announces CE mark for Pintuition: a non-radioactive localization system to improve breast cancer surgery
Sirius Medical, a MedTech startup, announced that it has received CE mark approval for Sirius Pintuition.
Today, Sirius Medical announces that Dr. Tibor Kovacs, Prof Isabel Rubio and Prof Jos van der Hage will join its clinical advisory board for marker-based tumor localization.
Today, Sirius Medical proudly announces that it has received ISO 13485:2016 certification for its Quality Management System (QMS) following review by its notified body, DEKRA.
We’ll be taking part in the 39th edition of the European Society of Surgical Oncology (ESSO39) congress in Rotterdam, the Netherlands.